K Pharma,Inc. AI Stock Analysis
Want to see JP:4896 full AI Analyst Report?
K Pharma,Inc. (4896) AI Stock Analysis
K Pharma,Inc.
(TSE/TYO:4896)
The score is primarily held down by weak financial performance (zero revenue in recent periods, sizable losses, sustained cash burn, and rising leverage with shrinking equity). Technical indicators add further pressure as the stock trades below all key moving averages with negative MACD and very weak momentum. Valuation provides limited offset because the negative P/E reflects unprofitability and no dividend yield data is available.
K Pharma,Inc. (4896) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 8.02B
- Dividend Yield
- ―
- Average Volume (3M)
- 21.94K
- Price to Earnings (P/E)
- -7.6
- Beta (1Y)
- 0.94
- Revenue Growth
- ―
- EPS Growth
- -20.34%
- Country
- Japan
- Employees
- 20
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
K Pharma,Inc. Business Overview & Revenue Model
Company Description
K Pharma, Inc., headquartered in Minato, Japan, was established in 2016 and operates within the Japanese market. The company is dedicated to the research, development, production, and sale of both regenerative medicines and pharmaceutical products. A...
K Pharma,Inc. Financial Statement Overview
Summary
Financial profile is meaningfully weakened: the income statement reflects a shift from profitability in 2023 to large losses in 2024–2025 with zero reported revenue, while cash flow remains materially negative (ongoing cash burn) and the balance sheet shows shrinking equity alongside rising leverage (~1.19x debt-to-equity). A modest improvement in 2025 cash burn is a small offset, but overall financial trajectory is challenged.
Income Statement
18Very NegativeBalance Sheet
34NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 1.00B | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 910.00M | 0 | -6.80M |
| EBITDA | -242.25M | -983.19M | -844.10M | 366.06M | -390.53M | -222.31M |
| Net Income | -250.58M | -993.23M | -846.46M | 260.33M | -392.43M | -228.72M |
Balance Sheet | ||||||
| Total Assets | 2.82B | 2.94B | 2.35B | 3.31B | 1.37B | 205.77M |
| Cash, Cash Equivalents and Short-Term Investments | 2.71B | 2.79B | 2.27B | 3.27B | 1.34B | 188.78M |
| Total Debt | 1.65B | 1.50B | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.81B | 1.67B | 94.76M | 209.13M | 38.30M | 26.88M |
| Stockholders Equity | 1.02B | 1.27B | 2.26B | 3.10B | 1.34B | 178.89M |
Cash Flow | ||||||
| Free Cash Flow | -929.19M | -929.19M | -998.21M | 444.62M | -393.44M | -196.32M |
| Operating Cash Flow | -918.00M | -918.00M | -983.72M | 454.43M | -363.48M | -196.32M |
| Investing Cash Flow | -54.68M | -54.68M | -14.49M | -11.10M | -32.74M | -250.00K |
| Financing Cash Flow | 1.50B | 1.50B | 0 | 1.49B | 1.54B | 368.20M |
K Pharma,Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4896, the sentiment is Negative. The current price of 686.00 is below the 20-day moving average (MA) of 693.95, below the 50-day MA of 752.48, and below the 200-day MA of 740.73, indicating a bearish trend. The MACD of -24.00 indicates Negative momentum. The RSI at 45.21 is Neutral, neither overbought nor oversold. The STOCH value of 60.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4896.
K Pharma,Inc. Peers Comparison
Overall Rating
JP:709656Neutral
JP:488049Neutral
JP:458346.9Neutral- JP:489640.85Neutral
JP:459438Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:7096 | 56Neutral | JPY 6.59B | 45.92 | ― | ― | 4.85% | -40.57% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4880 | 49Neutral | JPY 5.68B | 57.34 | ― | 1.75% | -9.94% | ― |
| JP:4583 | 47Neutral | JPY 6.71B | -6.19 | ― | ― | -13.40% | 7.50% |
| JP:4896 | 41Neutral | JPY 7.88B | -7.62 | ― | ― | ― | -20.34% |
| JP:4594 | 38Underperform | JPY 5.34B | -3.13 | ― | ― | -94.55% | -6.51% |
| JP:7776 | 26Underperform | JPY 6.90B | -5.90 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4896 | K Pharma,Inc. | 686.00 | 11.00 | 1.63% | |
| JP:4583 | Chiome Bioscience Inc. | 77.00 | -49.00 | -38.89% | |
| JP:4594 | BrightPath Biotherapeutics Co.Ltd. | 39.00 | -23.00 | -37.10% | |
| JP:4880 | CellSource Co., Ltd. | 281.00 | -227.00 | -44.69% | |
| JP:7096 | StemCell Institute | 668.00 | -141.00 | -17.43% | |
| JP:7776 | CellSeed Inc. | 171.00 | -261.00 | -60.42% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026